{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:32:57Z","timestamp":1773466377794,"version":"3.50.1"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,6]]},"DOI":"10.7759\/cureus.61790","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T10:01:54Z","timestamp":1717668114000},"source":"Crossref","is-referenced-by-count":5,"title":["Heart Failure With Improved Ejection Fraction: Prevalence, Predictors, and Guideline-Directed Medical Therapy"],"prefix":"10.7759","author":[{"given":"Sheethal G","family":"Oommen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruzhual K","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keerthi","family":"Talluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Nizam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejashwini","family":"Kohir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin A","family":"Aviles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Nino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi Gokulnath","family":"Jaisankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jashan","family":"Jaura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randev A","family":"Wannakuwatte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Tom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeby","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humza F","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-007-9008-3","article-title":"An introduction to acute heart failure syndromes: definition and classification","volume":"12","author":"Filippatos G","year":"2007","unstructured":"Filippatos G, Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev. 2007, 12:87-90. 10.1007\/s10741-007-9008-3","journal-title":"Heart Fail Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-017-0351-y","article-title":"Acute heart failure: definition, classification and epidemiology","volume":"14","author":"Kurmani S","year":"2017","unstructured":"Kurmani S, Squire I. Acute heart failure: definition, classification and epidemiology. Curr Heart Fail Rep. 2017, 14:385-92. 10.1007\/s11897-017-0351-y","journal-title":"Curr Heart Fail Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","unstructured":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017. a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018, 392:1789-858. 10.1016\/S0140-6736(18)32279-7","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American Heart Association","volume":"143","author":"Virani SS","year":"2021","unstructured":"Virani SS, Alonso A, Aparicio HJ, et al.. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021, 143:e254-743. 10.1161\/CIR.0000000000000950","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich PA","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA, et al.. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013, 6:606-19. 10.1161\/HHF.0b013e318291329a","journal-title":"Circ Heart Fail"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.10.028","article-title":"Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea","volume":"116","author":"Knudsen CW","year":"2004","unstructured":"Knudsen CW, Omland T, Clopton P, et al.. Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. Am J Med. 2004, 116:363-8. 10.1016\/j.amjmed.2003.10.028","journal-title":"Am J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/BF02599031","article-title":"How well can the chest radiograph diagnose left ventricular dysfunction?","volume":"11","author":"Badgett RG","year":"1996","unstructured":"Badgett RG, Mulrow CD, Otto PM, Ram\u00edrez G. How well can the chest radiograph diagnose left ventricular dysfunction?. J Gen Intern Med. 1996, 11:625-34. 10.1007\/BF02599031","journal-title":"J Gen Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2008.06.012","article-title":"Impact of echocardiography in patients hospitalized for heart failure: a prospective observational study","volume":"101","author":"Tribouilloy C","year":"2008","unstructured":"Tribouilloy C, Rusinaru D, Mahjoub H, Goissen T, L\u00e9vy F, Peltier M. Impact of echocardiography in patients hospitalized for heart failure: a prospective observational study. Arch Cardiovasc Dis. 2008, 101:465-73. 10.1016\/j.acvd.2008.06.012","journal-title":"Arch Cardiovasc Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101721","article-title":"Interchangeability in left ventricular ejection fraction measured by echocardiography and cardiovascular magnetic resonance: not a perfect match in the real world","volume":"48","author":"Clark J","year":"2023","unstructured":"Clark J, Ionescu A, Chahal CA, et al.. Interchangeability in left ventricular ejection fraction measured by echocardiography and cardiovascular magnetic resonance: not a perfect match in the real world. Curr Probl Cardiol. 2023, 48:101721. 10.1016\/j.cpcardiol.2023.101721","journal-title":"Curr Probl Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt B","year":"2021","unstructured":"Bozkurt B, Coats AJ, Tsutsui H, et al.. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021, 23:352-80. 10.1002\/ejhf.2115","journal-title":"Eur J Heart Fail"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1714\/3913.38959","article-title":"Heart failure with improved ejection fraction: practical guidance for the clinician [Article in Italian]","volume":"23","author":"Gori M","year":"2022","unstructured":"Gori M, Tinti MD, Gentile P, et al.. Heart failure with improved ejection fraction: practical guidance for the clinician [Article in Italian]. G Ital Cardiol (Rome). 2022, 23:924-31. 10.1714\/3913.38959","journal-title":"G Ital Cardiol (Rome)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2007.01.005","article-title":"Effect of cardiac resynchronization therapy on myocardial gene expression in patients with nonischemic dilated cardiomyopathy","volume":"13","author":"Iyengar S","year":"2007","unstructured":"Iyengar S, Haas G, Lamba S, et al.. Effect of cardiac resynchronization therapy on myocardial gene expression in patients with nonischemic dilated cardiomyopathy. J Card Fail. 2007, 13:304-11. 10.1016\/j.cardfail.2007.01.005","journal-title":"J Card Fail"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.111.257428","article-title":"Subcellular structures and function of myocytes impaired during heart failure are restored by cardiac resynchronization therapy","volume":"110","author":"Sachse FB","year":"2012","unstructured":"Sachse FB, Torres NS, Savio-Galimberti E, Aiba T, Kass DA, Tomaselli GF, Bridge JH. Subcellular structures and function of myocytes impaired during heart failure are restored by cardiac resynchronization therapy. Circ Res. 2012, 110:588-97. 10.1161\/CIRCRESAHA.111.257428","journal-title":"Circ Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s0008-6363(98)00121-7","article-title":"Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts","volume":"40","author":"Gray MO","year":"1998","unstructured":"Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res. 1998, 40:352-63. 10.1016\/s0008-6363(98)00121-7","journal-title":"Cardiovasc Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.12.7059","article-title":"Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice","volume":"96","author":"Engelhardt S","year":"1999","unstructured":"Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A. 1999, 96:7059-64. 10.1073\/pnas.96.12.7059","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000068316.53218.49","article-title":"Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure","volume":"107","author":"Reiken S","year":"2003","unstructured":"Reiken S, Wehrens XH, Vest JA, et al.. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation. 2003, 107:2459-66. 10.1161\/01.CIR.0000068316.53218.49","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.44.2.134","article-title":"Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy","volume":"44","author":"Swedberg K","year":"1980","unstructured":"Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J. 1980, 44:134-42. 10.1136\/hrt.44.2.134","journal-title":"Br Heart J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.80.3.551","article-title":"Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol","volume":"80","author":"Waagstein F","year":"1989","unstructured":"Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989, 80:551-63. 10.1161\/01.cir.80.3.551","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.86.2.431","article-title":"Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators","volume":"86","author":"Konstam MA","year":"1992","unstructured":"Konstam MA, Rousseau MF, Kronenberg MW, et al.. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation. 1992, 86:431-8. 10.1161\/01.cir.86.2.431","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.5318","article-title":"Dapagliflozin and mode of death in heart failure with improved ejection fraction: a post hoc analysis of the DELIVER trial","volume":"9","author":"Vardeny O","year":"2024","unstructured":"Vardeny O, Desai AS, Jhund PS, et al.. Dapagliflozin and mode of death in heart failure with improved ejection fraction: a post hoc analysis of the DELIVER trial. JAMA Cardiol. 2024, 9:283-9. 10.1001\/jamacardio.2023.5318","journal-title":"JAMA Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022, 145:e895-e1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.075","article-title":"Heart\u00a0failure with recovered left\u00a0ventricular ejection fraction: JACC scientific expert panel","volume":"76","author":"Wilcox JE","year":"2020","unstructured":"Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart\u00a0failure with recovered left\u00a0ventricular ejection fraction: JACC scientific expert panel. J Am Coll Cardiol. 2020, 76:719-34. 10.1016\/j.jacc.2020.05.075","journal-title":"J Am Coll Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.006855","article-title":"Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes","volume":"129","author":"Basuray A","year":"2014","unstructured":"Basuray A, French B, Ky B, et al.. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation. 2014, 129:2380-7. 10.1161\/CIRCULATIONAHA.113.006855","journal-title":"Circulation"},{"key":"ref24","unstructured":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. (2021). Accessed. April 28, 2024: https:\/\/secardiologia.es\/cientifico\/guias-clinicas\/insuficiencia-cardiaca-y-miocardiopatia\/12795-2021-esc-guidelines-...."},{"key":"ref25","unstructured":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. (2003). https.\/\/secardiologia.es\/cientifico\/guias-clinicas\/insuficiencia-cardiaca-y-miocardiopatia\/14537-2023-focused-update-...."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010","volume":"175","author":"Gerber Y","year":"2015","unstructured":"Gerber Y, Weston SA, Redfield MM, et al.. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015, 175:996-1004. 10.1001\/jamainternmed.2015.0924","journal-title":"JAMA Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.03.006","article-title":"Temporal trends in the incidence of\u00a0and\u00a0mortality associated with heart\u00a0failure with preserved and reduced ejection fraction","volume":"6","author":"Tsao CW","year":"2018","unstructured":"Tsao CW, Lyass A, Enserro D, et al.. Temporal trends in the incidence of\u00a0and\u00a0mortality associated with heart\u00a0failure with preserved and reduced ejection fraction. JACC Heart Fail. 2018, 6:678-85. 10.1016\/j.jchf.2018.03.006","journal-title":"JACC Heart Fail"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000350","article-title":"Heart disease and stroke statistics-2016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian D","year":"2016","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, et al.. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016, 133:e38-360. 10.1161\/CIR.0000000000000350","journal-title":"Circulation"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese G","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023, 118:3272-87. 10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2016.04.054","article-title":"Burden of heart failure in Latin America: a systematic review and meta-analysis","volume":"69","author":"Ciapponi A","year":"2016","unstructured":"Ciapponi A, Alcaraz A, Calder\u00f3n M, Matta MG, Chaparro M, Soto N, Bardach A. Burden of heart failure in Latin America: a systematic review and meta-analysis. Rev Esp Cardiol (Engl Ed). 2016, 69:1051-60. 10.1016\/j.rec.2016.04.054","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-016-0208-4","article-title":"Prevalence of heart failure in Australia: a systematic review","volume":"16","author":"Sahle BW","year":"2016","unstructured":"Sahle BW, Owen AJ, Mutowo MP, Krum H, Reid CM. Prevalence of heart failure in Australia: a systematic review. BMC Cardiovasc Disord. 2016, 16:32. 10.1186\/s12872-016-0208-4","journal-title":"BMC Cardiovasc Disord"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.07.006","article-title":"Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America","volume":"29","author":"Bozkurt B","year":"2023","unstructured":"Bozkurt B, Ahmad T, Alexander KM, et al.. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America. J Card Fail. 2023, 29:1412-51. 10.1016\/j.cardfail.2023.07.006","journal-title":"J Card Fail"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003123","article-title":"Heart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival: results from the valsartan heart failure trial","volume":"9","author":"Florea VG","year":"2016","unstructured":"Florea VG, Rector TS, Anand IS, Cohn JN. Heart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival: results from the valsartan heart failure trial. Circ Heart Fail. 2016, 9:e003123. 10.1161\/CIRCHEARTFAILURE.116.003123","journal-title":"Circ Heart Fail"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.770650","article-title":"A universal new definition of heart failure with improved ejection fraction for patients with coronary artery disease","volume":"12","author":"Huang H","year":"2021","unstructured":"Huang H, Liu J, Lei M, et al.. A universal new definition of heart failure with improved ejection fraction for patients with coronary artery disease. Front Physiol. 2021, 12:770650. 10.3389\/fphys.2021.770650","journal-title":"Front Physiol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1177\/2047487317750437","article-title":"Characteristics and prognosis of heart failure with improved compared with persistently reduced ejection fraction: a systematic review and meta-analyses","volume":"25","author":"J\u00f8rgensen ME","year":"2018","unstructured":"J\u00f8rgensen ME, Andersson C, Vasan RS, K\u00f8ber L, Abdulla J. Characteristics and prognosis of heart failure with improved compared with persistently reduced ejection fraction: a systematic review and meta-analyses. Eur J Prev Cardiol. 2018, 25:366-76. 10.1177\/2047487317750437","journal-title":"Eur J Prev Cardiol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.05.004","article-title":"Heart failure with improved\u00a0ejection\u00a0fraction: is it possible to escape one's past?","volume":"6","author":"Gulati G","year":"2018","unstructured":"Gulati G, Udelson JE. Heart failure with improved\u00a0ejection\u00a0fraction: is it possible to escape one's past?. JACC Heart Fail. 2018, 6:725-33. 10.1016\/j.jchf.2018.05.004","journal-title":"JACC Heart Fail"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.11.019","article-title":"Prevalence and prognostic implications of longitudinal ejection fraction change\u00a0in heart\u00a0failure","volume":"7","author":"Savarese G","year":"2019","unstructured":"Savarese G, Vedin O, D'Amario D, et al.. Prevalence and prognostic implications of longitudinal ejection fraction change\u00a0in heart\u00a0failure. JACC Heart Fail. 2019, 7:306-17. 10.1016\/j.jchf.2018.11.019","journal-title":"JACC Heart Fail"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2022.03.046","article-title":"Clinical characteristics, predictors, and outcomes of heart failure with improved ejection fraction","volume":"357","author":"Su K","year":"2022","unstructured":"Su K, Li M, Wang L, Tian S, Su J, Gu J, Chen S. Clinical characteristics, predictors, and outcomes of heart failure with improved ejection fraction. Int J Cardiol. 2022, 357:72-80. 10.1016\/j.ijcard.2022.03.046","journal-title":"Int J Cardiol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13345","article-title":"Frequency, predictors, and prognosis of heart failure with improved left ventricular ejection fraction: a single-centre retrospective observational cohort study","volume":"8","author":"Li Q","year":"2021","unstructured":"Li Q, Qiao Y, Tang J, et al.. Frequency, predictors, and prognosis of heart failure with improved left ventricular ejection fraction: a single-centre retrospective observational cohort study. ESC Heart Fail. 2021, 8:2755-64. 10.1002\/ehf2.13345","journal-title":"ESC Heart Fail"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.757596","article-title":"Prevalence and prognosis of HFimpEF developed from patients with heart failure with reduced ejection fraction: systematic review and meta-analysis","volume":"8","author":"He Y","year":"2021","unstructured":"He Y, Ling Y, Guo W, et al.. Prevalence and prognosis of HFimpEF developed from patients with heart failure with reduced ejection fraction: systematic review and meta-analysis. Front Cardiovasc Med. 2021, 8:757596. 10.3389\/fcvm.2021.757596","journal-title":"Front Cardiovasc Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14619","article-title":"Incidence and predictors of heart failure with improved ejection fraction category in a HFrEF patient population","volume":"11","author":"Solymossi B","year":"2024","unstructured":"Solymossi B, Muk B, Sepp R, et al.. Incidence and predictors of heart failure with improved ejection fraction category in a HFrEF patient population. ESC Heart Fail. 2024, 11:783-94. 10.1002\/ehf2.14619","journal-title":"ESC Heart Fail"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.000570","article-title":"Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long\u2010term follow\u2010up: does real healing exist?","volume":"4","author":"Merlo M","year":"2015","unstructured":"Merlo M, Stolfo D, Anzini M, et al.. Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long\u2010term follow\u2010up: does real healing exist?. J Am Heart Assoc. 2015, 4:e001504. 10.1161\/JAHA.114.000570","journal-title":"J Am Heart Assoc"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13630","article-title":"Characteristics and outcomes of heart failure with recovered left ventricular ejection fraction","volume":"8","author":"Zhang X","year":"2021","unstructured":"Zhang X, Sun Y, Zhang Y, et al.. Characteristics and outcomes of heart failure with recovered left ventricular ejection fraction. ESC Heart Fail. 2021, 8:5383-91. 10.1002\/ehf2.13630","journal-title":"ESC Heart Fail"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz233","article-title":"Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study","volume":"40","author":"Ghimire A","year":"2019","unstructured":"Ghimire A, Fine N, Ezekowitz JA, Howlett J, Youngson E, McAlister FA. Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. Eur Heart J. 2019, 40:2110-7. 10.1093\/eurheartj\/ehz233","journal-title":"Eur Heart J"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.824","article-title":"Recovered heart failure with reduced ejection fraction and outcomes: a prospective study","volume":"19","author":"Lup\u00f3n J","year":"2017","unstructured":"Lup\u00f3n J, D\u00edez-L\u00f3pez C, de Antonio M, et al.. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Eur J Heart Fail. 2017, 19:1615-23. 10.1002\/ejhf.824","journal-title":"Eur J Heart Fail"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011077","article-title":"Characteristics, outcomes, and treatment of heart failure with improved ejection fraction","volume":"8","author":"Park CS","year":"2019","unstructured":"Park CS, Park JJ, Mebazaa A, et al.. Characteristics, outcomes, and treatment of heart failure with improved ejection fraction. J Am Heart Assoc. 2019, 8:e011077. 10.1161\/JAHA.118.011077","journal-title":"J Am Heart Assoc"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2017.0103","article-title":"Heart failure with recovered ejection fraction: clinical characteristics, determinants and prognosis. CARDIOCHUS-CHOP registry","volume":"25","author":"Agra Bermejo R","year":"2018","unstructured":"Agra Bermejo R, Gonzalez Babarro E, L\u00f3pez Canoa JN, et al.. Heart failure with recovered ejection fraction: clinical characteristics, determinants and prognosis. CARDIOCHUS-CHOP registry. Cardiol J. 2018, 25:353-62. 10.5603\/CJ.a2017.0103","journal-title":"Cardiol J"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2017.09.005","article-title":"Heart failure with recovered ejection fraction in African Americans: results from the African-American heart failure trial","volume":"24","author":"Chang KW","year":"2018","unstructured":"Chang KW, Beri N, Nguyen NH, et al.. Heart failure with recovered ejection fraction in African Americans: results from the African-American heart failure trial. J Card Fail. 2018, 24:303-9. 10.1016\/j.cardfail.2017.09.005","journal-title":"J Card Fail"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.1325","article-title":"Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction","volume":"1","author":"Kalogeropoulos AP","year":"2016","unstructured":"Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, et al.. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol. 2016, 1:510-8. 10.1001\/jamacardio.2016.1325","journal-title":"JAMA Cardiol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002826","article-title":"Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes","volume":"9","author":"Nadruz W Jr","year":"2016","unstructured":"Nadruz W Jr, West E, Santos M, Skali H, Groarke JD, Forman DE, Shah AM. Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes. Circ Heart Fail. 2016, 9:e002826. 10.1161\/CIRCHEARTFAILURE.115.002826","journal-title":"Circ Heart Fail"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1159\/000447287","article-title":"Heart failure with recovered ejection fraction in a cohort of elderly patients with chronic heart failure","volume":"135","author":"Trull\u00e0s JC","year":"2016","unstructured":"Trull\u00e0s JC, Manzano L, Formiga F, et al.. Heart failure with recovered ejection fraction in a cohort of elderly patients with chronic heart failure. Cardiology. 2016, 135:196-201. 10.1159\/000447287","journal-title":"Cardiology"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2486","article-title":"The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HF","volume":"24","author":"DeVore AD","year":"2022","unstructured":"DeVore AD, Hellkamp AS, Thomas L, et al.. The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HF. Eur J Heart Fail. 2022, 24:762-70. 10.1002\/ejhf.2486","journal-title":"Eur J Heart Fail"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.06.1309","article-title":"Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study (Investigations of Pregnancy-Associated Cardiomyopathy)","volume":"66","author":"McNamara DM","year":"2015","unstructured":"McNamara DM, Elkayam U, Alharethi R, et al.. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015, 66:905-14. 10.1016\/j.jacc.2015.06.1309","journal-title":"J Am Coll Cardiol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2017.10.002","article-title":"Patient characteristics in variable left ventricular recovery from Takotsubo syndrome","volume":"19","author":"Kim JI","year":"2018","unstructured":"Kim JI, Yerasi C, Azzouqa A, et al.. Patient characteristics in variable left ventricular recovery from Takotsubo syndrome. Cardiovasc Revasc Med. 2018, 19:247-50. 10.1016\/j.carrev.2017.10.002","journal-title":"Cardiovasc Revasc Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16658","article-title":"Association of cardiac resynchronization therapy with change in left ventricular ejection fraction in patients with chemotherapy-induced cardiomyopathy","volume":"322","author":"Singh JP","year":"2019","unstructured":"Singh JP, Solomon SD, Fradley MG, et al.. Association of cardiac resynchronization therapy with change in left ventricular ejection fraction in patients with chemotherapy-induced cardiomyopathy. JAMA. 2019, 322:1799-805. 10.1001\/jama.2019.16658","journal-title":"JAMA"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.115.003283","article-title":"Outcomes after implantable cardioverter-defibrillator generator replacement for primary prevention of sudden cardiac death","volume":"9","author":"Madhavan M","year":"2016","unstructured":"Madhavan M, Waks JW, Friedman PA, et al.. Outcomes after implantable cardioverter-defibrillator generator replacement for primary prevention of sudden cardiac death. Circ Arrhythm Electrophysiol. 2016, 9:e003283. 10.1161\/CIRCEP.115.003283","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1111\/pace.12868","article-title":"Arrhythmic risk following recovery of left ventricular ejection fraction in patients with primary prevention ICD","volume":"39","author":"Berthelot-Richer M","year":"2016","unstructured":"Berthelot-Richer M, Bonenfant F, Clavel MA, et al.. Arrhythmic risk following recovery of left ventricular ejection fraction in patients with primary prevention ICD. Pacing Clin Electrophysiol. 2016, 39:680-9. 10.1111\/pace.12868","journal-title":"Pacing Clin Electrophysiol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.1413","article-title":"Association of implantable cardioverter defibrillators with survival in patients with and without improved ejection fraction: secondary analysis of the Sudden Cardiac Death in Heart Failure Trial","volume":"2","author":"Adabag S","year":"2017","unstructured":"Adabag S, Patton KK, Buxton AE, et al.. Association of implantable cardioverter defibrillators with survival in patients with and without improved ejection fraction: secondary analysis of the Sudden Cardiac Death in Heart Failure Trial. JAMA Cardiol. 2017, 2:767-74. 10.1001\/jamacardio.2017.1413","journal-title":"JAMA Cardiol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.011283","article-title":"Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial","volume":"130","author":"Ruwald MH","year":"2014","unstructured":"Ruwald MH, Solomon SD, Foster E, et al.. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation. 2014, 130:2278-86. 10.1161\/CIRCULATIONAHA.114.011283","journal-title":"Circulation"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.08.048","article-title":"Parameters of repolarization heterogeneity are associated with myocardial recovery in acute heart failure","volume":"301","author":"Prenner SB","year":"2020","unstructured":"Prenner SB, Swat SA, Ng J, Baldridge A, Wilcox JE. Parameters of repolarization heterogeneity are associated with myocardial recovery in acute heart failure. Int J Cardiol. 2020, 301:147-51. 10.1016\/j.ijcard.2019.08.048","journal-title":"Int J Cardiol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.06.062","article-title":"Myocardial recovery and the failing heart: myth, magic, or molecular target?","volume":"60","author":"Mann DL","year":"2012","unstructured":"Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target?. J Am Coll Cardiol. 2012, 60:2465-72. 10.1016\/j.jacc.2012.06.062","journal-title":"J Am Coll Cardiol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505517","article-title":"Shared genetic predisposition in peripartum and dilated cardiomyopathies","volume":"374","author":"Ware JS","year":"2016","unstructured":"Ware JS, Li J, Mazaika E, et al.. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med. 2016, 374:233-41. 10.1056\/NEJMoa1505517","journal-title":"N Engl J Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006832","article-title":"Clinical phenotypes and prognosis of dilated cardiomyopathy caused by truncating variants in the TTN Gene","volume":"13","author":"Akhtar MM","year":"2020","unstructured":"Akhtar MM, Lorenzini M, Cicerchia M, et al.. Clinical phenotypes and prognosis of dilated cardiomyopathy caused by truncating variants in the TTN Gene. Circ Heart Fail. 2020, 13:e006832. 10.1161\/CIRCHEARTFAILURE.119.006832","journal-title":"Circ Heart Fail"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.3390\/cells12050783","article-title":"Epigenetics in LMNA-related cardiomyopathy","volume":"12","author":"Wang Y","year":"2023","unstructured":"Wang Y, Dobreva G. Epigenetics in LMNA-related cardiomyopathy. Cells. 2023, 12:783. 10.3390\/cells12050783","journal-title":"Cells"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.06.004","article-title":"Imaging, biomarker, and clinical predictors of cardiac remodeling in\u00a0heart\u00a0failure with reduced ejection fraction","volume":"7","author":"Aimo A","year":"2019","unstructured":"Aimo A, Gaggin HK, Barison A, Emdin M, Januzzi JL Jr. Imaging, biomarker, and clinical predictors of cardiac remodeling in\u00a0heart\u00a0failure with reduced ejection fraction. JACC Heart Fail. 2019, 7:782-94. 10.1016\/j.jchf.2019.06.004","journal-title":"JACC Heart Fail"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.10.014","article-title":"NT-proBNP goal achievement is\u00a0associated with significant reverse\u00a0remodeling and improved clinical outcomes in HFrEF","volume":"7","author":"Daubert MA","year":"2019","unstructured":"Daubert MA, Adams K, Yow E, et al.. NT-proBNP goal achievement is\u00a0associated with significant reverse\u00a0remodeling and improved clinical outcomes in HFrEF. JACC Heart Fail. 2019, 7:158-68. 10.1016\/j.jchf.2018.10.014","journal-title":"JACC Heart Fail"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.031560","article-title":"Prognostic value of high-sensitivity troponin T in chronic heart failure: an individual patient data meta-analysis","volume":"137","author":"Aimo A","year":"2018","unstructured":"Aimo A, Januzzi JL Jr, Vergaro G, et al.. Prognostic value of high-sensitivity troponin T in chronic heart failure: an individual patient data meta-analysis. Circulation. 2018, 137:286-97. 10.1161\/CIRCULATIONAHA.117.031560","journal-title":"Circulation"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10105-w","article-title":"Biomarkers for the diagnosis and management of heart failure","volume":"27","author":"Castiglione V","year":"2022","unstructured":"Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev. 2022, 27:625-43. 10.1007\/s10741-021-10105-w","journal-title":"Heart Fail Rev"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3390\/children10071138","article-title":"Elevated copeptin levels are associated with heart failure severity and adverse outcomes in children with cardiomyopathy","volume":"10","author":"Karki KB","year":"2023","unstructured":"Karki KB, Towbin JA, Shah SH, Philip RR, West AN, Tadphale SD, Saini A. Elevated copeptin levels are associated with heart failure severity and adverse outcomes in children with cardiomyopathy. Children (Basel). 2023, 10:1138. 10.3390\/children10071138","journal-title":"Children (Basel)"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v3.i1.10","article-title":"Evaluation of chronic kidney disease in chronic heart failure: from biomarkers to arterial renal resistances","volume":"3","author":"Iacoviello M","year":"2015","unstructured":"Iacoviello M, Leone M, Antoncecchi V, Ciccone MM. Evaluation of chronic kidney disease in chronic heart failure: from biomarkers to arterial renal resistances. World J Clin Cases. 2015, 3:10-9. 10.12998\/wjcc.v3.i1.10","journal-title":"World J Clin Cases"},{"key":"ref71","article-title":"Correlation between serum urea nitrogen, cystatin C, homocysteine, and chronic heart failure","volume":"13","author":"Yao Z","year":"2021","unstructured":"Yao Z, Li G, Li G. Correlation between serum urea nitrogen, cystatin C, homocysteine, and chronic heart failure. Am J Transl Res. 2021, 13:3254-61.","journal-title":"Am J Transl Res"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.3122","article-title":"Decreased renal function is associated with heart failure readmissions","volume":"10","author":"Vindhyal MR","year":"2018","unstructured":"Vindhyal MR, Khayyat S, Shaaban A, Duran BA, Kallail KJ. Decreased renal function is associated with heart failure readmissions. Cureus. 2018, 10:e3122. 10.7759\/cureus.3122","journal-title":"Cureus"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003788","article-title":"Abnormal global longitudinal strain predicts future deterioration of left ventricular function in heart failure patients with a recovered left ventricular ejection fraction","volume":"10","author":"Adamo L","year":"2017","unstructured":"Adamo L, Perry A, Novak E, Makan M, Lindman BR, Mann DL. Abnormal global longitudinal strain predicts future deterioration of left ventricular function in heart failure patients with a recovered left ventricular ejection fraction. Circ Heart Fail. 2017, 10:e003788. 10.1161\/CIRCHEARTFAILURE.116.003788","journal-title":"Circ Heart Fail"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009841","article-title":"Baseline longitudinal strain predicts recovery of left ventricular ejection fraction in hospitalized patients with nonischemic cardiomyopathy","volume":"7","author":"Swat SA","year":"2018","unstructured":"Swat SA, Cohen D, Shah SJ, et al.. Baseline longitudinal strain predicts recovery of left ventricular ejection fraction in hospitalized patients with nonischemic cardiomyopathy. J Am Heart Assoc. 2018, 7:e09841. 10.1161\/JAHA.118.009841","journal-title":"J Am Heart Assoc"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.10.043","article-title":"Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy","volume":"250","author":"Barison A","year":"2018","unstructured":"Barison A, Aimo A, Ortalda A, et al.. Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. Int J Cardiol. 2018, 250:195-200. 10.1016\/j.ijcard.2017.10.043","journal-title":"Int J Cardiol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2141","article-title":"Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: a systematic review and meta-analysis","volume":"23","author":"Turgeon RD","year":"2021","unstructured":"Turgeon RD, Barry AR, Hawkins NM, Ellis UM. Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: a systematic review and meta-analysis. Eur J Heart Fail. 2021, 23:578-89. 10.1002\/ejhf.2141","journal-title":"Eur J Heart Fail"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-023-00435-5","article-title":"Comparative efficacy of different drugs for the treatment of dilated cardiomyopathy: a systematic review and network meta-analysis","volume":"23","author":"Tong X","year":"2023","unstructured":"Tong X, Shen L, Zhou X, Wang Y, Chang S, Lu S. Comparative efficacy of different drugs for the treatment of dilated cardiomyopathy: a systematic review and network meta-analysis. Drugs R D. 2023, 23:197-210. 10.1007\/s40268-023-00435-5","journal-title":"Drugs R D"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan M","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, et al.. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022, 400:757-67. 10.1016\/S0140-6736(22)01429-5","journal-title":"Lancet"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-022-00945-z","article-title":"Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis","volume":"27","author":"Wang Y","year":"2022","unstructured":"Wang Y, Gao T, Meng C, Li S, Bi L, Geng Y, Zhang P. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis. Eur J Med Res. 2022, 27:314. 10.1186\/s40001-022-00945-z","journal-title":"Eur J Med Res"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1632","article-title":"Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment","volume":"22","author":"Nauta JF","year":"2020","unstructured":"Nauta JF, Hummel YM, Tromp J, et al.. Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. Eur J Heart Fail. 2020, 22:1147-55. 10.1002\/ejhf.1632","journal-title":"Eur J Heart Fail"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14233","article-title":"Adaptive versus maladaptive right ventricular remodelling","volume":"10","author":"Rako ZA","year":"2023","unstructured":"Rako ZA, Kremer N, Yogeswaran A, Richter MJ, Tello K. Adaptive versus maladaptive right ventricular remodelling. ESC Heart Fail. 2023, 10:762-75. 10.1002\/ehf2.14233","journal-title":"ESC Heart Fail"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072090","article-title":"Endothelial dysfunction: a contributor to adverse cardiovascular remodeling and heart failure development in type 2 diabetes beyond accelerated atherogenesis","volume":"9","author":"Gamrat A","year":"2020","unstructured":"Gamrat A, Surdacki MA, Chyrchel B, Surdacki A. Endothelial dysfunction: a contributor to adverse cardiovascular remodeling and heart failure development in type 2 diabetes beyond accelerated atherogenesis. J Clin Med. 2020, 9:2090. 10.3390\/jcm9072090","journal-title":"J Clin Med"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0000000000000834","article-title":"Unresolved issues in left ventricular postischemic remodeling and progression to heart failure","volume":"20","author":"Gronda E","year":"2019","unstructured":"Gronda E, Sacchi S, Benincasa G, Vanoli E, Napoli C. Unresolved issues in left ventricular postischemic remodeling and progression to heart failure. J Cardiovasc Med (Hagerstown). 2019, 20:640-9. 10.2459\/JCM.0000000000000834","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186742","article-title":"Matrix metalloproteinases and tissue inhibitors of metalloproteinases in extracellular matrix remodeling during left ventricular diastolic dysfunction and heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"21","author":"Krebber MM","year":"2020","unstructured":"Krebber MM, van Dijk CG, Vernooij RW, et al.. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in extracellular matrix remodeling during left ventricular diastolic dysfunction and heart failure with preserved ejection fraction: a systematic review and meta-analysis. Int J Mol Sci. 2020, 21:6742. 10.3390\/ijms21186742","journal-title":"Int J Mol Sci"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1813","article-title":"MiRNA-181a is a novel regulator of aldosterone-mineralocorticoid receptor-mediated cardiac remodelling","volume":"22","author":"Garg A","year":"2020","unstructured":"Garg A, Foinquinos A, Jung M, et al.. MiRNA-181a is a novel regulator of aldosterone-mineralocorticoid receptor-mediated cardiac remodelling. Eur J Heart Fail. 2020, 22:1366-77. 10.1002\/ejhf.1813","journal-title":"Eur J Heart Fail"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.08.014","article-title":"Left ventricular post-infarct remodeling: implications for systolic function improvement and outcomes\u00a0in the modern era","volume":"8","author":"van der Bijl P","year":"2020","unstructured":"van der Bijl P, Abou R, Goedemans L, et al.. Left ventricular post-infarct remodeling: implications for systolic function improvement and outcomes\u00a0in the modern era. JACC Heart Fail. 2020, 8:131-40. 10.1016\/j.jchf.2019.08.014","journal-title":"JACC Heart Fail"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.870924","article-title":"Cardiac remodeling in heart failure: role of pyroptosis and its therapeutic implications","volume":"9","author":"Chai R","year":"2022","unstructured":"Chai R, Xue W, Shi S, et al.. Cardiac remodeling in heart failure: role of pyroptosis and its therapeutic implications. Front Cardiovasc Med. 2022, 9:870924. 10.3389\/fcvm.2022.870924","journal-title":"Front Cardiovasc Med"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00576-x","article-title":"Cardiac metabolic remodelling in chronic kidney disease","volume":"18","author":"Patel N","year":"2022","unstructured":"Patel N, Yaqoob MM, Aksentijevic D. Cardiac metabolic remodelling in chronic kidney disease. Nat Rev Nephrol. 2022, 18:524-37. 10.1038\/s41581-022-00576-x","journal-title":"Nat Rev Nephrol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01602-0","article-title":"Transplantation of human induced pluripotent stem cell-derived cardiomyocytes improves myocardial function and reverses ventricular remodeling in infarcted rat hearts","volume":"11","author":"Guan X","year":"2020","unstructured":"Guan X, Xu W, Zhang H, et al.. Transplantation of human induced pluripotent stem cell-derived cardiomyocytes improves myocardial function and reverses ventricular remodeling in infarcted rat hearts. Stem Cell Res Ther. 2020, 11:73. 10.1186\/s13287-020-01602-0","journal-title":"Stem Cell Res Ther"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12681","article-title":"Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature","volume":"7","author":"Bajaj NS","year":"2020","unstructured":"Bajaj NS, Gupta K, Gharpure N, Pate M, Chopra L, Kalra R, Prabhu SD. Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature. ESC Heart Fail. 2020, 7:1319-30. 10.1002\/ehf2.12681","journal-title":"ESC Heart Fail"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.12662","article-title":"Angiotensin receptor-neprilysin inhibition (ARNI) therapy and reverse remodeling in heart failure with reduced ejection fraction","volume":"322","author":"Drazner MH","year":"2019","unstructured":"Drazner MH. Angiotensin receptor-neprilysin inhibition (ARNI) therapy and reverse remodeling in heart failure with reduced ejection fraction. JAMA. 2019, 322:1051-3. 10.1001\/jama.2019.12662","journal-title":"JAMA"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008410","article-title":"Association between angiotensin receptor-neprilysin inhibition, cardiovascular biomarkers, and cardiac remodeling in heart failure with reduced ejection fraction","volume":"14","author":"Murphy SP","year":"2021","unstructured":"Murphy SP, Prescott MF, Maisel AS, et al.. Association between angiotensin receptor-neprilysin inhibition, cardiovascular biomarkers, and cardiac remodeling in heart failure with reduced ejection fraction. Circ Heart Fail. 2021, 14:e008410. 10.1161\/CIRCHEARTFAILURE.120.008410","journal-title":"Circ Heart Fail"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105573","article-title":"Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: a systematic review and network meta-analysis of randomized clinical trials","volume":"169","author":"Bao J","year":"2021","unstructured":"Bao J, Kan R, Chen J, Xuan H, Wang C, Li D, Xu T. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: a systematic review and network meta-analysis of randomized clinical trials. Pharmacol Res. 2021, 169:105573. 10.1016\/j.phrs.2021.105573","journal-title":"Pharmacol Res"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1177\/2042018819861593","article-title":"Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes","volume":"10","author":"Gulsin GS","year":"2019","unstructured":"Gulsin GS, Kanagala P, Chan DC, et al.. Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes. Ther Adv Endocrinol Metab. 2019, 10:2042018819861593. 10.1177\/2042018819861593","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-022-10220-5","article-title":"Sodium-glucose cotransporter 2 inhibitors and cardiac remodeling","volume":"15","author":"Salah HM","year":"2022","unstructured":"Salah HM, Verma S, Santos-Gallego CG, et al.. Sodium-glucose cotransporter 2 inhibitors and cardiac remodeling. J Cardiovasc Transl Res. 2022, 15:944-56. 10.1007\/s12265-022-10220-5","journal-title":"J Cardiovasc Transl Res"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S213910","article-title":"Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats","volume":"13","author":"Zheng RH","year":"2019","unstructured":"Zheng RH, Bai XJ, Zhang WW, et al.. Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats. Drug Des Devel Ther. 2019, 13:2745-57. 10.2147\/DDDT.S213910","journal-title":"Drug Des Devel Ther"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15333","article-title":"Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling","volume":"179","author":"R\u00fcdebusch J","year":"2022","unstructured":"R\u00fcdebusch J, Benkner A, Nath N, et al.. Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling. Br J Pharmacol. 2022, 179:2430-42. 10.1111\/bph.15333","journal-title":"Br J Pharmacol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu204","article-title":"New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes","volume":"35","author":"Senni M","year":"2014","unstructured":"Senni M, Paulus WJ, Gavazzi A, et al.. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J. 2014, 35:2797-815. 10.1093\/eurheartj\/ehu204","journal-title":"Eur Heart J"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday BP","year":"2019","unstructured":"Halliday BP, Wassall R, Lota AS, et al.. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019, 393:61-73. 10.1016\/S0140-6736(18)32484-X","journal-title":"Lancet"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/s0828-282x(09)70497-0","article-title":"Recovery and recurrence of left ventricular systolic dysfunction in patients with idiopathic dilated cardiomyopathy","volume":"25","author":"Moon J","year":"2009","unstructured":"Moon J, Ko YG, Chung N, Ha JW, Kang SM, Choi EY, Rim SJ. Recovery and recurrence of left ventricular systolic dysfunction in patients with idiopathic dilated cardiomyopathy. Can J Cardiol. 2009, 25:e147-50. 10.1016\/s0828-282x(09)70497-0","journal-title":"Can J Cardiol"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199800003-00006","article-title":"Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature","volume":"32 Suppl 1","author":"van Campen LC","year":"1998","unstructured":"van Campen LC, Visser FC, Visser CA. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J Cardiovasc Pharmacol. 1998, 32 Suppl 1:S31-5. 10.1097\/00005344-199800003-00006","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf S","year":"1991","unstructured":"Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991, 325:293-302. 10.1056\/NEJM199108013250501","journal-title":"N Engl J Med"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn JN","year":"2001","unstructured":"Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001, 345:1667-75. 10.1056\/NEJMoa010713","journal-title":"N Engl J Med"},{"key":"ref104","article-title":"Ejection fraction improvement and reverse remodeling achieved with sacubitril\/valsartan in heart failure with reduced ejection fraction patients","volume":"7","author":"Almufleh A","year":"2017","unstructured":"Almufleh A, Marbach J, Chih S, Stadnick E, Davies R, Liu P, Mielniczuk L. Ejection fraction improvement and reverse remodeling achieved with sacubitril\/valsartan in heart failure with reduced ejection fraction patients. Am J Cardiovasc Dis. 2017, 7:108-13.","journal-title":"Am J Cardiovasc Dis"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/s0195-668x(03)00477-9","article-title":"Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure","volume":"24","author":"McKelvie RS","year":"2003","unstructured":"McKelvie RS, Rouleau JL, White M, et al.. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J. 2003, 24:1727-34. 10.1016\/s0195-668x(03)00477-9","journal-title":"Eur Heart J"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.5455\/medarh.2023.77.105-111","article-title":"The effectiveness of eplerenone vs spironolactone on left ventricular systolic function, hospitalization and cardiovascular death in patients with chronic heart failure-HFrEF","volume":"77","author":"Naser N","year":"2023","unstructured":"Naser N, Durak-Nalbantic A, Sabanovic-Bajramovic N, Karic A. The effectiveness of eplerenone vs spironolactone on left ventricular systolic function, hospitalization and cardiovascular death in patients with chronic heart failure-HFrEF. Med Arch. 2023, 77:105-11. 10.5455\/medarh.2023.77.105-111","journal-title":"Med Arch"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.12.001","article-title":"Omecamtiv mecarbil in chronic heart\u00a0failure with reduced ejection fraction: rationale and design of GALACTIC-HF","volume":"8","author":"Teerlink JR","year":"2020","unstructured":"Teerlink JR, Diaz R, Felker GM, et al.. Omecamtiv mecarbil in chronic heart\u00a0failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC Heart Fail. 2020, 8:329-40. 10.1016\/j.jchf.2019.12.001","journal-title":"JACC Heart Fail"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-021-01580-6","article-title":"Vericiguat for heart failure with reduced ejection fraction","volume":"23","author":"Lombardi CM","year":"2021","unstructured":"Lombardi CM, Cimino G, Pagnesi M, et al.. Vericiguat for heart failure with reduced ejection fraction. Curr Cardiol Rep. 2021, 23:144. 10.1007\/s11886-021-01580-6","journal-title":"Curr Cardiol Rep"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2013.02.017","article-title":"Significance of follow-up left ventricular ejection fraction measurements in the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation trial (DEFINITE)","volume":"10","author":"Schliamser JE","year":"2013","unstructured":"Schliamser JE, Kadish AH, Subacius H, Shalaby A, Schaechter A, Levine J, Goldberger JJ. Significance of follow-up left ventricular ejection fraction measurements in the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation trial (DEFINITE). Heart Rhythm. 2013, 10:838-46. 10.1016\/j.hrthm.2013.02.017","journal-title":"Heart Rhythm"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2024.01.014","article-title":"Heart failure with improved ejection fraction: beyond diagnosis to trajectory analysis","volume":"82","author":"Pensa AV","year":"2024","unstructured":"Pensa AV, Khan SS, Shah RV, Wilcox JE. Heart failure with improved ejection fraction: beyond diagnosis to trajectory analysis. Prog Cardiovasc Dis. 2024, 82:102-12. 10.1016\/j.pcad.2024.01.014","journal-title":"Prog Cardiovasc Dis"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.19-211","article-title":"Recovered left ventricular ejection fraction and its prognostic impacts in hospitalized heart failure patients with reduced ejection fraction","volume":"61","author":"Abe S","year":"2020","unstructured":"Abe S, Yoshihisa A, Ichijo Y, et al.. Recovered left ventricular ejection fraction and its prognostic impacts in hospitalized heart failure patients with reduced ejection fraction. Int Heart J. 2020, 61:281-8. 10.1536\/ihj.19-211","journal-title":"Int Heart J"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.0939","article-title":"Quality of life in patients with heart failure with recovered ejection fraction","volume":"6","author":"Wohlfahrt P","year":"2021","unstructured":"Wohlfahrt P, Nativi-Nicolau J, Zhang M, et al.. Quality of life in patients with heart failure with recovered ejection fraction. JAMA Cardiol. 2021, 6:957-62. 10.1001\/jamacardio.2021.0939","journal-title":"JAMA Cardiol"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.06.047","article-title":"Risk of appropriate implantable cardioverter-defibrillator therapies and sudden cardiac death in patients with heart failure with improved left ventricular ejection fraction","volume":"213","author":"Al-Sadawi M","year":"2024","unstructured":"Al-Sadawi M, Gier C, Tao M, et al.. Risk of appropriate implantable cardioverter-defibrillator therapies and sudden cardiac death in patients with heart failure with improved left ventricular ejection fraction. Am J Cardiol. 2024, 213:55-62. 10.1016\/j.amjcard.2023.06.047","journal-title":"Am J Cardiol"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.113.000813","article-title":"Long-term functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after \u03b2-blocker therapy","volume":"7","author":"de Groote P","year":"2014","unstructured":"de Groote P, Fertin M, Duva Pentiah A, Go\u00e9minne C, Lamblin N, Bauters C. Long-term functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after \u03b2-blocker therapy. Circ Heart Fail. 2014, 7:434-9. 10.1161\/CIRCHEARTFAILURE.113.000813","journal-title":"Circ Heart Fail"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031093","article-title":"Factors associated with maintenance of an improved ejection fraction: an echocardiogram-based registry study","volume":"12","author":"McElderry B","year":"2023","unstructured":"McElderry B, O'Neill T, Griffin BP, Kalahasti V, Barzilai B, Brateanu A. Factors associated with maintenance of an improved ejection fraction: an echocardiogram-based registry study. J Am Heart Assoc. 2023, 12:e031093. 10.1161\/JAHA.123.031093","journal-title":"J Am Heart Assoc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/260036-heart-failure-with-improved-ejection-fraction-prevalence-predictors-and-guideline-directed-medical-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T10:02:01Z","timestamp":1717668121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/260036-heart-failure-with-improved-ejection-fraction-prevalence-predictors-and-guideline-directed-medical-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":115,"URL":"https:\/\/doi.org\/10.7759\/cureus.61790","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,6]]}}}